Efficacy data on teriparatide (parathyroid hormone) in patients with postmenopausal osteoporosis

Joint Bone Spine

Volumn 70, Issue 6, 2003, Pages 465-470

  Debiais, Françoise ^a  

^a University of Poitiers   (France)

Author keywords

Anabolic agents; Parathyroid hormone; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCITONIN; CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DIGOXIN; ESTROGEN; GROWTH FACTOR; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN; PYRIDINOLINE; RALOXIFENE; TELOPEPTIDE; VITAMIN D;

APOPTOSIS; BONE DENSITY; BONE MASS; BONE MINERAL; BONE MINERALIZATION; BONE STRUCTURE; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FRAGILITY FRACTURE; HEADACHE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; MUSCLE CRAMP; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOSARCOMA; OUTCOMES RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; VERTIGO;

EID: 0346102686     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2003.08.002     Document Type: Conference Paper

References (31)

1. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralisation of bone tissue in osteoporotic women. Bone 2000;27:687-94.
2. Marie P, de Vernejoul MC. Facteurs systémiques et locaux du remodelage osseux. In: Kuntz D, editor. Maladies métaboliques osseuses de l'adulte. Flammarion Ed; 1996. p. 49-68.
3. Rubin MR, Cosman F, Lindsay R, Bilezikian JP. The anabolic effects of parathyroid hormone. Osteoporos Int 2002;13:267-77.
4. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, et al. Catabolic effects of continuous human PTH(1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001;142:4047-54.
5. Locklin RM, Khosla S, Riggs BL. Mechanisms of biphasic anabolic and catabolic effects of parathyroid hormone (PTH) on bone cells. Bone 2001;28(Suppl):S80 [abstract].
6. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.
7. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM, et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976;1:1035-8.
8. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980;280:1340-4.
9. Lindsay R, Hodsman A, Genant H, Bolognese M, Ettinger M, for the PTH, working group. A randomized controlled multi-center study of 1-84 hPTH for treatment of postmenopausal osteoporosis. Bone 1998;23(Suppl 1):S175 [abstract].
10. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34.
11. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41.
12. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23.
13. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomised double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35.
14. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among post-menopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
15. Cosman F, Nieves J, Woelfert L, Formica C, Gordaon S, Shen V, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925-31.
16. Roe EB, Sanchez SD, del Puerto GA, Pierini E, Bacchetti P, Cann CE, et al. Parathyroid hormone 1-34 (hPTH1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis. Results from a placebo-controlled randomised trial. J Bone Miner Res 1999;14(Suppl 1):S137 [abstract].
17. Cosman F, Nieves J, Woelfert L, Formica C, Shen V, Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13:1051-5.
18. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MHL. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodelling system? Bone 1995;16:603-10.
19. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, et al. A randomised controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620-8.
20. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, et al. New bone formation with teriparatide[human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003;144:2008-15.
21. Ettinger B, San Martin JA, Crans G, Pavo I. Early response of bone turnover markers and bone mineral density to teriparatide [recombinant human parathyroid hormone (1-34)] in postmenopausal women previously treated with an antiresorptive drug. J Bone Miner Res 2002;17(Suppl 1):S157 [abstract].
22. Hodsman AB, Fraher L, Adachi J. A clinical trial of cyclical clodronate as maintenance therapy following withdrawal of parathyroid hormone, in the treatment of post-menopausal osteoporosis. J Bone Miner Res 1995;10(Suppl 1):S200 [abstract].
23. Bradbeer JN, Arlot ME, Meunier PJ, Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH1-34) and estrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol 1992;37:282-9.
24. Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH (1-34) therapy in women with severe osteoporosis. Bone 2000;27:311-8.
25. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.
26. Zanchetta JR, Bogado C, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in post-menopausal women with osteoporosis. J Bone Miner Res 2003;18:539-43.
27. Benson CT, Voelker JR. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. Clin Pharmacol Ther 2003;73:87-94.
28. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21.
29. Betancourt M, Wirfel KL, Raumond AK, Yasko AW, Lee J, Vassilopoulou-Sellin R. Osteosarcoma of bone in a patient with primary hyperparathyroidism: a case report. J Bone Miner Res 2003;18:163-6.
30. Black DM, Rosen CM, Greenspan S, Ensrud K, Bilezikian J, Hue T, et al. Parathyroid hormone (PTH) and alendronate in the treatment of osteoporosis: PaTH trial update. J Bone Miner Res 2002;17(Suppl 1):S378 [abstract].
31. Neer R, Hayes A, Rao A, Finkelstein J. Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 2002;17(Suppl 1):S135 [abstract].